TY - JOUR
T1 - Evaluating Congruence Between Clinical and Biological Staging Across The Alzheimer’s Disease Spectrum
AU - Zalzale, Hussein
AU - Madeiros, Marina Scop
AU - Soares, Carolina
AU - Bauer-Negrini, Guilherme
AU - Povala, Guilherme
AU - Ferreira, Pamela C.L.
AU - Amaral, Livia
AU - Lussier, Firoza Z.
AU - Bellaver, Bruna
AU - Abbas, Sarah
AU - Rodrigues, Matheus Scarpatto
AU - Tudorascu, Dana
AU - Oliveira, Markley
AU - Felix, Cynthia
AU - Leffa, Douglas Teixeira
AU - Tissot, Cécile
AU - Aguzzoli, Cristiano Schaffer
AU - Ruppert, Emma Patrice
AU - Saha, Pampa
AU - Rahmouni, Nesrine
AU - Zetterberg, Henrik
AU - Blennow, Kaj
AU - Ashton, Nicholas J.
AU - Pascual, Belen
AU - Gordon, Brian A.
AU - Jagust, William J.
AU - Lowe, Val J.
AU - Karikari, Thomas K.
AU - Oh, Hwamee
AU - Klunk, William E.
AU - Soleimani-Meigooni, David N.
AU - Rosa-Neto, Pedro
AU - Baker, Suzanne L.
AU - Pascoal, Tharick A.
N1 - Publisher Copyright:
© 2024 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2024/12/1
Y1 - 2024/12/1
N2 - BACKGROUND: The newly proposed criteria by the AA working group incorporates both biological and clinical stages to characterize the progression of AD. In this study, we aim to evaluate the agreement between these two complementary systems. METHODS: Using 188 participants from McGill TRIAD and 139 from the HEAD cohorts, we categorized participants into biological (0-4) and clinical (0-4) stages using amyloid PET, tau PET(MK-6240), and clinical measures as described by the working group. Participants were then stratified into three categories: congruent (clinical = biological), higher in the biological stage (clinical < biological), and higher in the clinical stage (clinical > biological). In the TRIAD cohort, we further compared these groups for age, sex, years of education, vascular burden (WMH), microglial activation (PBR scan), Astrocyte reactivity (GFAP), amyloid load, tau load, and NPI-Q scores using Welch two-sided t-test with FDR multiple comparison correction. RESULTS: In the TRIAD cohort, 34% of participants were congruent, 24.5% had a higher clinical stage, and 41.5% had a higher biological stage. Meanwhile in the HEAD cohort 68.2% were congruent, 20.7% had a higher clinical stage, and 17% had a higher biological stage. TRIAD participants with a higher clinical stage had lower education (P = 0.02), more neuropsychiatric symptoms (P = 0.03), and a higher vascular burden (P = 0.03) (Table 1). As expected, people with higher biological stage had more amyloid(P<0.001), tau(P<0.001), and astrocyte reactivity(P<0.001) (Table 1, Figure 2). CONCLUSIONS: Our findings highlight important discordance between clinical and biological stages, which could be partially explained by cognitive reserve. This was supported by the protective effects of educational attainment in participants with a higher biological stage. Vascular burden played a major role in the cognitive impairment of individuals with higher clinical stages. Future studies should replicate these findings in larger more representative population-based cohorts.
AB - BACKGROUND: The newly proposed criteria by the AA working group incorporates both biological and clinical stages to characterize the progression of AD. In this study, we aim to evaluate the agreement between these two complementary systems. METHODS: Using 188 participants from McGill TRIAD and 139 from the HEAD cohorts, we categorized participants into biological (0-4) and clinical (0-4) stages using amyloid PET, tau PET(MK-6240), and clinical measures as described by the working group. Participants were then stratified into three categories: congruent (clinical = biological), higher in the biological stage (clinical < biological), and higher in the clinical stage (clinical > biological). In the TRIAD cohort, we further compared these groups for age, sex, years of education, vascular burden (WMH), microglial activation (PBR scan), Astrocyte reactivity (GFAP), amyloid load, tau load, and NPI-Q scores using Welch two-sided t-test with FDR multiple comparison correction. RESULTS: In the TRIAD cohort, 34% of participants were congruent, 24.5% had a higher clinical stage, and 41.5% had a higher biological stage. Meanwhile in the HEAD cohort 68.2% were congruent, 20.7% had a higher clinical stage, and 17% had a higher biological stage. TRIAD participants with a higher clinical stage had lower education (P = 0.02), more neuropsychiatric symptoms (P = 0.03), and a higher vascular burden (P = 0.03) (Table 1). As expected, people with higher biological stage had more amyloid(P<0.001), tau(P<0.001), and astrocyte reactivity(P<0.001) (Table 1, Figure 2). CONCLUSIONS: Our findings highlight important discordance between clinical and biological stages, which could be partially explained by cognitive reserve. This was supported by the protective effects of educational attainment in participants with a higher biological stage. Vascular burden played a major role in the cognitive impairment of individuals with higher clinical stages. Future studies should replicate these findings in larger more representative population-based cohorts.
UR - http://www.scopus.com/inward/record.url?scp=85214491719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85214491719&partnerID=8YFLogxK
U2 - 10.1002/alz.093241
DO - 10.1002/alz.093241
M3 - Article
C2 - 39750098
AN - SCOPUS:85214491719
SN - 1552-5260
VL - 20
JO - Alzheimer's & dementia : the journal of the Alzheimer's Association
JF - Alzheimer's & dementia : the journal of the Alzheimer's Association
IS - S3
M1 - e093241
ER -